ArticleClinical and experimental immunology2010
Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease.
Article in Clinical and experimental immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 93 citations in OpenAlex.
- Advances in mesenchymal stem cell therapy for lupus nephritis.World journal of stem cells · 2025Review
- Adipose-derived mesenchymal stem cell therapy for connective tissue diseases and complications.Inflammation and regeneration · 2024Review
- hUC-MSC transplantation therapy effects on lupus-prone MRL/lpr mice at early disease stages.Stem cell research & therapy · 2023Article
- Cross Talk between Mesenchymal Stem/Stromal Cells and Innate Immunocytes Concerning Lupus Disease.Stem cell reviews and reports · 2022Review
- Immunomodulatory Activity of Mesenchymal Stem Cells in Lupus Nephritis: Advances and Applications.Frontiers in immunology · 2022Review
- Cell Based Treatment of Autoimmune Diseases in Children.Frontiers in pediatrics · 2022Review
- Mesenchymal stem cell-based therapy for autoimmune diseases: emerging roles of extracellular vesicles.Molecular biology reports · 2019Review
- Xenogeneic Transplantation of Human Placenta-Derived Mesenchymal Stem Cells Alleviates Renal Injury and Reduces Inflammation in a Mouse Model of Lupus Nephritis.BioMed research international · 2019Article
- Critical Role of Tumor Necrosis Factor Signaling in Mesenchymal Stem Cell-Based Therapy for Autoimmune and Inflammatory Diseases.Frontiers in immunology · 2018Review
- Mesenchymal Stem Cells in Primary Sjögren's Syndrome: Prospective and Challenges.Stem cells international · 2018Review
- Treatment with Allogenic Mesenchymal Stromal Cells in a Murine Model of Systemic Lupus Erythematosus.International journal of stem cells · 2017Article
- Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Perspectives for Systemic Sclerosis.Clinical reviews in allergy & immunology · 2017Review
- CD117Stem cell research & therapy · 2017Article
- Bone Marrow Mesenchymal Stem Cells Enhance the Differentiation of Human Switched Memory B Lymphocytes into Plasma Cells in Serum-Free Medium.Journal of immunology research · 2016Article
- Human embryonic stem cell-derived mesenchymal cells preserve kidney function and extend lifespan in NZB/W F1 mouse model of lupus nephritis.Scientific reports · 2015Article
- Update on mesenchymal stem cell-based therapy in lupus and scleroderma.Arthritis research & therapy · 2015Review
- New strategies for overcoming limitations of mesenchymal stem cell-based immune modulation.International journal of stem cells · 2015Review
- Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models.World journal of stem cells · 2015Review
- Bone marrow stromal cells as immunomodulators. A primer for dermatologists.Journal of dermatological science · 2015Review
- Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications.Journal of immunology research · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cell (MSC) therapy has shown promise clinically in graft-versus-host disease and in preclinical animal models of T helper type 1 (Th1)-driven autoimmune diseases, but whether MSCs can be used to treat autoimmune disease in general is unclear. Here, the therapeutic potential of MSCs was tested in the New Zealand black (NZB)xNew Zealand white (NZW) F1 (NZB/W) lupus mouse model. The pathogenesis of systemic lupus erythematosus involves abnormal B and T cell activation leading to autoantibody formation. To test whether the immunomodulatory activity of MSCs would inhibit the development of autoimmune responses and provide a therapeutic benefit, NZB/W mice were treated with Balb/c-derived allogeneic MSCs starting before or after disease onset. Systemic MSC administration worsened disease and enhanced anti-double-stranded DNA (dsDNA) autoantibody production. The increase in autoantibody titres was accompanied by an increase in plasma cells in the bone marrow, an increase in glomerular immune complex deposition, more severe kidney pathology, and greater proteinuria. Co-culturing MSCs with plasma cells purified from NZB/W mice led to an increase in immunoglobulin G antibody production, suggesting that MSCs might be augmenting plasma cell survival and function in MSC-treated animals. Our results suggest that MSC therapy may not be beneficial in Th2-type T cell- and B cell-driven diseases such as lupus and highlight the need to understand further the appropriate application of MSC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.